Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today reported results for the quarter ended September 30, 2023.
Related news for (CORT)
- CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- Cushing Syndrome Pipeline Insight 2024, Featuring Key Players Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals and Key Products Relacorilant, SPI 62 and CRN-04894
- corcept therapeutics announces third quarter financial results, positive results from phase 3 gradient trial in patients with cushing’s syndrome and provides corporate update
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
